Sommaire

• • ·Statins in acute coronary syndromes: The sooner, the better?

    Page :377-380

    Gregory G. Schwartz

    Plan Plan
• • ·Change of address box

    Page :380

    
• • ·Statin therapy—Time to turn the focus from efficacy to implementation?

    Page :381-383

    Michael Blazing

    
• • ·Plaque regression—A new target for antiatherosclerotic therapy

    Page :384-387

    Juhana Karha, Deepak L. Bhatt

    Plan Plan  
• • ·New-onset paroxysmal atrial fibrillation: Is permanence inevitable?

    Page :388-390

    Kristen K. Patton, Richard L. Page

    
• • ·Prevalence of anemia and effects on mortality in patients with heart failure

    Page :391-401

    JoAnn Lindenfeld

    Résumé Résumé Plan Plan  
• • ·Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention

    Page :402-407

    Paul W. Armstrong, Peter X. Adams, Hussein R. Al-Khalidi, Christian Hamm, David Holmes, William O'Neill, Thomas G. Todaro, Alec Vahanian, Frans Van de Werf, Christopher B. Granger, on behalf of the APEX-AMI Steering Committee

    Plan Plan  
• • ·Rationale—Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease

    Page :408-413

    T.-Christian H. Mix, Robert M. Brenner, Mark E. Cooper, Dick de Zeeuw, Peter Ivanovich, Andrew S. Levey, Janet B. McGill, John J.V. McMurray, Patrick S. Parfrey, Hans-Henrik Parving, Brian J.G. Pereira, Giuseppe Remuzzi, Ajay K. Singh, Scott D. Solomon, Catherine Stehman-Breen, Robert D. Toto, Marc A. Pfeffer

    Résumé Résumé Plan Plan  
• • ·Primary stenting of occluded native coronary arteries II—Rationale and design of the PRISON II study: A randomized comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of chronic total coronary occlusions

    Page :414.e1

    Braim M. Rahel, Gert J. Laarman, Maarten J. Suttorp, on behalf of the PRISON II study investigators

    Résumé Résumé Plan Plan
• • ·Coronary drug-eluting stent development: Issues in trial design

    Page :415-433

    Neal I. Muni, Robert M. Califf, Jonette R. Foy, Ashley B. Boam, Bram D. Zuckerman, Richard E. Kuntz

    Plan Plan  
• • ·Conducting economic evaluations alongside multinational clinical trials: Toward a research consensus

    Page :434-443

    Shelby D. Reed, Kevin J. Anstrom, Ameet Bakhai, Andrew H. Briggs, Robert M. Califf, David J. Cohen, Michael F. Drummond, Henry A. Glick, Ari Gnanasakthy, Mark A. Hlatky, Bernie J. O'Brien, Frank M. Torti, Anastasios A. Tsiatis, Andrew R. Willan, Daniel B. Mark, Kevin A. Schulman

    Résumé Résumé Plan Plan  
• • ·Early initiation of lipid-lowering therapy for acute coronary syndromes improves compliance with guideline recommendations: Observations from the Orbofiban in Patients with Unstable Coronary Syndromes (OPUS–TIMI 16) trial

    Page :444-450

    Charles S. Smith, Christopher P. Cannon, Carolyn H. McCabe, Sabina A. Murphy, Jane Bentley, Eugene Braunwald

    Résumé Résumé Plan Plan  
• • ·Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: Results of a randomized, double-blind, placebo-controlled study

    Page :451-457

    Stella M. Macin, Eduardo R. Perna, Eduardo F. Farías, Valeria Franciosi, Jorge R. Cialzeta, Mónica Brizuela, Fernanda Medina, Carlos Tajer, Hernan Doval, Reynaldo Badaracco

    Résumé Résumé Plan Plan  
• • ·Electrocardiographic damage scores and cardiovascular mortality

    Page :458-463

    Kelly Richardson, Gregory Engel, Takuya Yamazaki, Sung Chun, Victor F. Froelicher

    Résumé Résumé Plan Plan  
• • ·Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: The Vytorin Versus Atorvastatin (VYVA) Study

    Page :464-473

    Christie M. Ballantyne, Nicola Abate, Zhong Yuan, Thomas R. King, Joanne Palmisano

    Résumé Résumé Plan Plan  
• • ·Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients

    Page :473.e1

    Stefan John, Markus P. Schneider, Christian Delles, Johannes Jacobi, Roland E. Schmieder

    Résumé Résumé Plan Plan  
• • ·Influence of clinical trial enrollment on the quality of care and outcomes for patients with non–ST-segment elevation acute coronary syndromes

    Page :474-481

    David E. Kandzari, Matthew T. Roe, Anita Y. Chen, Barbara L. Lytle, Charles V. Pollack, Robert A. Harrington, E. Magnus Ohman, W. Brian Gibler, Eric D. Peterson

    Résumé Résumé Plan Plan
• • ·Reducing the costs of phase III cardiovascular clinical trials

    Page :482-488

    Eric L. Eisenstein, Philip W. Lemons, Barbara E. Tardiff, Kevin A. Schulman, M. King Jolly, Robert M. Califf

    Résumé Résumé Plan Plan
• • ·Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: Results from the Canadian Registry of Atrial Fibrillation

    Page :489-496

    Charles R. Kerr, Karin H. Humphries, Mario Talajic, George J. Klein, Stuart J. Connolly, Martin Green, John Boone, Robert Sheldon, Paul Dorian, David Newman

    Résumé Résumé Plan Plan  
• • ·Left ventricular systolic asynchrony after acute myocardial infarction in patients with narrow QRS complexes

    Page :497-503

    Yan Zhang, Anna K.Y. Chan, Cheuk-Man Yu, Wynnie W.M. Lam, Gabriel W.K. Yip, Wing-Hong Fung, Nina M.C. So, Mei Wang, John E. Sanderson

    Résumé Résumé Plan Plan  
• • ·Long-term benefits of an early invasive management in acute coronary syndromes depend on intracoronary stenting and aggressive antiplatelet treatment: A metaregression

    Page :504-511

    Giuseppe G.L. Biondi-Zoccai, Antonio Abbate, Pierfrancesco Agostoni, Luca Testa, Francesco Burzotta, Marzia Lotrionte, Carlo Trani, Luigi M. Biasucci

    Résumé Résumé Plan Plan  
• • ·Association of chronic kidney disease with clinical outcomes after coronary revascularization: The arterial revascularization therapies study (ARTS)

    Page :512-519

    Joachim H. Ix, Nestor Mercado, Michael G. Shlipak, Pedro A. Lemos, Eric Boersma, Wietze Lindeboom, William W. O'Neill, William Wijns, Patrick W. Serruys

    Résumé Résumé Plan Plan  
• • ·Simvastatin does not inhibit intimal hyperplasia and restenosis but promotes plaque regression in normocholesterolemic patients undergoing coronary stenting: A randomized study with intravascular ultrasound

    Page :520-526

    Anna Sonia Petronio, Giovanni Amoroso, Ugo Limbruno, Barbara Papini, Marco De Carlo, Andrea Micheli, Nicola Ciabatti, Mario Mariani

    Résumé Résumé Plan Plan  
• • ·Exercise treadmill testing using a modified exercise protocol in women with suspected myocardial ischemia: Findings from the National Heart, Lung and Blood Institute–sponsored Women's Ischemia Syndrome Evaluation (WISE)

    Page :527-533

    Jannet F. Lewis, Susan McGorray, Lang Lin, Carl J. Pepine, Bernard Chaitman, Mark Doyle, Daniel Edmundowicz, Barry L. Sharaf, C. Noel Bairey Merz

    Résumé Résumé Plan Plan  
• • ·Prediction of death or myocardial infarction by exercise single photon emission computed tomography perfusion scintigraphy in patients who have had recent coronary artery stenting

    Page :534-540

    Vivek Rajagopal, Hitinder S. Gurm, Richard C. Brunken, Claire E. Pothier, Deepak L. Bhatt, Michael S. Lauer

    Résumé Résumé Plan Plan  
• • ·Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure

    Page :541-547

    Robert P. Frantz, Lyle J. Olson, Diane Grill, Soundos K. Moualla, Susan M. Nelson, Thomas P. Nobrega, Richard D. Hanna, Richard J. Backes, Farouk Mookadam, Denise Heublein, Kent R. Bailey, John C. Burnett

    Résumé Résumé Plan Plan  
• • ·Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Valsartan Heart Failure Trial (Val-HeFT)

    Page :548-557

    Aldo P. Maggioni, Roberto Latini, Peter E. Carson, Steven N. Singh, Simona Barlera, Robert Glazer, Serge Masson, Elisabetta Cerè, Gianni Tognoni, Jay N. Cohn, for the Val-HeFT Investigators

    Résumé Résumé Plan Plan  
• • ·Patients with heart failure who die in hospice

    Page :558-564

    Cheryl Hoyt Zambroski, Debra K. Moser, Lynn P. Roser, Seongkum Heo, Misook L. Chung

    Résumé Résumé Plan Plan  
• • ·Very early cardiac magnetic resonance imaging for quantification of myocardial tissue perfusion in patients receiving tirofiban before percutaneous coronary intervention for ST-elevation myocardial infarction

    Page :564.e1

    Henning Steen, Stephanie Lehrke, Uwe K.H. Wiegand, Constanze Merten, Lydia Schuster, Gert Richardt, Christian Kulke, Hans B. Gehl, Joao A. Lima, Hugo A. Katus, Evangelos Giannitsis

    Résumé Résumé Plan Plan  
• • ·Is atorvastatin more appropriate to use in combination with niacin than simvastatin in patients with the metabolic syndrome?

    Page :e17

    Moutasim H. Al-Shaer

    
• • ·Angiotensin-converting enzyme inhibitors as a new therapy for atrial fibrillation? Controversy

    Page :e19

    Akiyoshi Ogimoto, Yuji Shigematsu, Jitsuo Higaki, Tetsuro Miki

    
• • ·Letter to the editor

    Page :e21

    Jeff Nagge, Olavo Fernandes, Jin Huh

    
• • ·Reply

    Page :e23

    Michael W. Kruse, Jeremy J. Lee

    
• • ·TOC

    Page :A2

    
• • ·Editorial Board

    Page :A6

    
• • ·Information for Authors

    Page :A7

    
• • ·Information for Readers

    Page :A10